Adesan

Quick links to important sections

Adesan

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adesan

What is Adesan? (Overview)

Adesan is a prescription-only (Rx) brand-name medication primarily used for the long-term management of high blood pressure (hypertension) and the treatment of chronic heart failure in adults. Its active pharmaceutical ingredient is candesartan cilexetil.

Property Description
Active Ingredient Candesartan Cilexetil
Brand Name Adesan
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Regulatory Status Prescription Only (Rx)
Dosage Form Oral tablet

Function and Classification

Candesartan cilexetil is classified as a prodrug, meaning it is initially inactive but converts into its active therapeutic form, candesartan, once absorbed by the body.

Candesartan belongs to a class of medicines known as Angiotensin II Receptor Blockers (ARBs). This class of drug acts by selectively blocking the AT1 receptor, which prevents the hormone Angiotensin II from causing blood vessels to narrow. This action helps to relax and widen blood vessels, which is the primary mechanism for lowering blood pressure.

The candesartan molecule is considered a standard therapy for both hypertension and heart failure. This signifies its established role in cardiovascular medicine. Adesan is formulated as a single-agent tablet and is not a cure for chronic conditions, but rather an essential part of a long-term management plan.


Brand Differentiation

As a prescription brand, Adesan contains candesartan cilexetil as its sole active component. While it contains the same active ingredient found in generic versions of candesartan cilexetil, the Adesan brand provides a distinct product identity, such as specific tablet appearance, for patient and medical tracking. Its single-agent formulation is utilized when a patient requires the specific effect of the ARB without the addition of other active substances, such as diuretics.

Regulatory References

  1. Candesartan - StatPearls - NCBI Bookshelf

What side effects are possible with Adesan?

Possible side effects and safety information

The safety profile of Adesan (candesartan cilexetil) is based on the classification of adverse reactions documented in official government regulatory documents. These documents categorize potential effects across various physiological systems and define specific safety constraints for use.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency of occurrence observed in clinical use:

  • Common: Adverse effects frequently listed in regulatory documents include dizziness, headache, back pain, and certain upper respiratory tract infections.
  • Uncommon: These reactions include hypotension (low blood pressure) and nausea.
  • Very Rare: Effects that occur infrequently but are officially documented include blood disorders such as agranulocytosis, metabolic changes like hyperkalaemia, reactions affecting the liver (hepatitis), and severe allergic reactions like angioedema.

Serious Safety Considerations

The official labeling highlights several serious adverse reactions and usage restrictions. Angioedema (swelling of the face, lips, or throat) is considered a serious hypersensitivity concern. The medicine is contraindicated for use during the second and third trimesters of pregnancy due to the potential for fetal injury and death. Specific constraints also apply to patients with severe hepatic impairment (liver) and those receiving simultaneous dual therapy that blocks the renin-angiotensin system, such as combination with aliskiren in certain patient groups.

Safety Patterns and Monitoring

Regulatory safety information notes that certain effects, particularly changes in renal function and hypotension, may require specific monitoring, especially during the period following the first dose and subsequent dose increases in patients with chronic heart failure. Adverse reactions are grouped across multiple system-organ classes, including the Nervous System, Vascular System, Hepatobiliary System, and Blood and Lymphatic System.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a clear and immediate protocol for managing a suspected overdose of Adesan, emphasizing the risk even in the absence of initial symptoms.


Documented Overdose Symptoms

Symptoms that may occur following an overdose are generally related to the central nervous and cardiovascular systems, and may include:

  • Headache
  • Feeling sick (nausea)
  • Dizziness
  • Very tired (weariness)

Required Emergency Action

Immediate medical attention is required for any suspected overdose of Adesan. You must immediately telephone a doctor, a Poisons Information Centre, or go to the Accident and Emergency department at the nearest hospital for advice.

This urgent action must be taken even if there are no signs of discomfort or poisoning at the time of the call. Regulatory documents stress that the patient may need urgent medical attention to monitor the body's response and provide necessary care.

The regulatory profile highlights the immediate need for professional assessment for any exposure that exceeds the intended use, regardless of whether the patient currently feels unwell.

Therapeutic Uses of Adesan

What Adesan Treats: Main Uses and Benefits

Adesan is considered relevant for managing conditions characterized by systemic discomfort, specifically two cardiovascular areas, in adults and certain pediatric groups. The overall therapeutic goal is to manage symptoms related to systemic imbalance and to provide support that helps ease the overall symptom burden. Within clinical practice, the medication is applied across specific therapeutic areas.

The medication is applied in addressing conditions marked by increased physiological stress, relevant in clinical settings for essential hypertension and symptomatic chronic heart failure (NYHA Class II-IV) in adults, and for hypertension in certain children aged 1 to 16.

How Adesan Supports Patients

The medication is used for managing symptom clusters related to fluid overload, such as alleviating peripheral edema (swelling) and reducing related fatigue and shortness of breath that interfere with daily stability. This assists with maintaining functional stability and supports the patient during difficult episodes by easing distress. Adesan is considered relevant in conditions marked by increased physiological stress, particularly for patients who have hypertension alongside co-existing conditions like diabetes. This supports general well-being during symptomatic phases, as controlling pressure helps ease the overall symptom burden.


Quick Fact: Support for Fluid Overload Symptoms

Adesan may assist with easing symptoms like swelling and fatigue associated with systemic imbalance in chronic heart failure.

Regulatory References

  1. DailyMed information from the NIH

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Adesan — Official Regulatory Information

The eligibility profile for Adesan (candesartan cilexetil) is strictly defined by government regulatory bodies based on age, physiological state, and existing medical conditions.

Populations for whom use is allowed (as stated in label):

  • Adults (18+ years): Approved for both hypertension and heart failure.
  • Children and Adolescents (1 to <17 years): Approved for hypertension only.

Contraindicated and Restricted Use

Official labeling establishes absolute prohibitions and mandates special caution for several populations:

Classification Population/Condition Restriction Basis
Contraindicated Pregnancy (2nd and 3rd trimesters) Risk of fetal injury and death. Discontinuation is required upon detection of pregnancy.
Contraindicated Severe Hepatic Impairment / Cholestasis Increased drug effects and known risks in severe liver dysfunction.
Contraindicated Children aged below 1 year Safety and efficacy have not been established; absolute prohibition for hypertension.
Contraindicated Diabetes Mellitus + use of Aliskiren Risk associated with dual blockade of the Renin-Angiotensin System.
Restricted Use Volume/Salt Depletion Requires correction of the fluid status or close medical supervision before starting therapy.
Not Recommended Nursing/Breastfeeding Mothers Official guidance recommends discontinuing either the drug or nursing.
Not Established Pediatric patients with GFR < 30 mL/min/1.73 m^2 Safety and efficacy have not been studied in children with severe renal impairment.

Older adults are generally eligible for use, though some may exhibit greater sensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adesan (candesartan cilexetil) has officially documented interaction patterns primarily centered on pharmacodynamic effects related to blood pressure and electrolyte balance, as stated in regulatory labeling.

Official Interaction Statements

Classification Interacting Agents (Classes or Specific Medicines) Documented Outcome / Restriction
Contraindicated Combination Aliskiren Contraindicated in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min) due to the increased risks of hypotension, hyperkalemia, and reduced renal function.
High-Risk PD Interaction Potassium-Sparing Diuretics, Potassium Supplements, Potassium-Containing Salt Substitutes, Heparin Co-administration may lead to an increased risk of hyperkalemia (high serum potassium levels).
Renal/Antihypertensive PD Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Selective COX-2 Inhibitors May lead to an increased risk of deterioration of renal function and a reduction of the antihypertensive effect (blood pressure lowering).
Exposure Alteration Lithium Co-administration has been reported to cause reversible increases in serum lithium concentrations and toxicity.

Additional Regulatory Information

  • Dual RAS Blockade: The combination of Adesan with an ACE Inhibitor and a Mineralocorticoid Receptor Antagonist for heart failure is generally not recommended.
  • Metabolic Profile: Candesartan is not significantly metabolized by the CYP450 enzyme system, and therefore major metabolic drug-drug interactions are not expected.
  • Food/Alcohol: Adesan may be administered with or without food. Alcohol may have an additive effect in lowering blood pressure.
  • Population Note: The risk of renal function deterioration with NSAIDs is greater in the elderly and in patients who are volume-depleted.

Mechanism of Action

How Adesan Works

Adesan acts primarily by binding to the Adesan-Receptor system, a specific set of receptors located in key regulatory pathways. Its interaction mechanism is classified as allosteric modulation, where it attaches to a site on the receptor distinct from the natural binding site. This allosteric binding event induces a conformational change in the receptor structure, thereby adjusting the receptor's sensitivity and functional response to the body's endogenous signaling molecules.

This molecular interaction subsequently modifies the signal transduction cascade. Specifically, Adesan influences the initial coupling efficiency and activity of G-protein-associated pathways and their downstream secondary messenger molecules. By affecting these early steps, Adesan introduces a mechanistic interference that reduces the amplification of signaling through the targeted cascade. The resulting physiological consequence is the localized dampening of excessive cellular activity within the receptor-associated systems, leading to a controlled adjustment that influences the overall physiological output of these pathways.

Dosage and Administration Information

How to Use Adesan (Candesartan Cilexetil) — Administration Guidelines

Adesan is an oral tablet that is taken once daily. The tablet should be swallowed whole with water and may be taken with or without food. The medication should be taken at approximately the same time each day to maintain consistent exposure.


Dosing Instructions by Condition

The dosage of Adesan must be determined and individualized by a healthcare provider based on the patient's condition and response. Dosing typically follows these established clinical protocols:

  • Adult Hypertension: The usual recommended initial dose is 16 mg once daily. The total daily dose range is typically 8 mg to 32 mg.
  • Adult Heart Failure: The recommended initial dose is 4 mg once daily. The dose is gradually increased, ideally targeting a dose of 32 mg once daily, by doubling the dose at intervals of at least two weeks, as tolerated.

Administration Rules and Special Patient Populations

Area Rule
Missed Dose Do not take a double dose. Skip the missed dose and take the next dose at the usual time if it is almost time for the next scheduled dose.
Preparation Tablets must be swallowed whole. Candesartan monotherapy tablets should not be crushed or chewed.
Renal/Hepatic Impairment A lower starting dose (e.g., 4 mg once daily) should be considered for patients with severe renal or moderate hepatic impairment.
Pediatric Use Approved for hypertension in children aged 6 to <17 years, with dosing adjusted based on body weight. Use in children younger than 1 year is not recommended.

These instructions define the prescribed dosage, frequency, and specific method for taking the medicine, establishing the proper therapeutic procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adesan

Evidence for Use in Essential Hypertension (High Blood Pressure)

Research has been conducted on Adesan for essential hypertension. This evidence base is primarily built upon short-term Randomized Controlled Trials (RCTs) that compared Adesan with a placebo (a non-active substance) or with other blood pressure medications. Research examined how blood pressure measurements, specifically systolic and diastolic readings, changed over defined time intervals, usually between 8 to 12 weeks.

In these trials, Research monitored changes in blood pressure, reporting measured differences in systolic and diastolic readings. Longer-term observational studies were observed in adult populations to track the occurrence of major clinical events. These findings describe patterns observed in the studies that contribute to understanding the evidence landscape for hypertension.

Evidence for Use in Chronic Heart Failure

Adesan was evaluated in patients with symptomatic chronic heart failure, especially those with reduced left ventricular ejection fraction. The evidence was derived from large-scale, multi-year clinical trial programs. These trials research examined severe clinical events, primarily monitoring the rates of cardiovascular death and hospitalization due to heart failure. Functional status, such as changes in the patient's daily activity level, was studied for as a secondary outcome.

These major programs reported how symptoms evolved in the observed populations, describing patterns related to the combined endpoint related to mortality and hospitalization. The research describes measured differences in these serious event rates when comparing the studied groups to placebo. However, research exploring the benefit in heart failure patients who have a preserved ejection fraction (HFpEF) was observed in some studies to be less consistent, with outcomes being more varied across different measured endpoints.


What is Still Uncertain About Adesan's Research

Although the research base is extensive for the approved uses, some questions may still be considered open in the scientific community. For example, data are still emerging regarding the research findings of Adesan in heart failure patients who have a preserved ejection fraction because subgroup findings are uncertain and often varied across studies. Similarly, for pediatric populations, while short-term data exists for blood pressure monitoring, there is limited information for long-term outcomes regarding the tracking of cardiovascular events.

Key Studies & References

  1. Hypertension in adults: diagnosis and management (NICE Guideline NG136)

Frequently Asked Questions (FAQ)

Common questions about Adesan (FAQ)

Q: How quickly should I expect Adesan to start lowering my blood pressure?

According to official product information and clinical study data, most of the medication's blood pressure lowering effect is typically observed within two weeks of beginning treatment. The full therapeutic effect is generally achieved after four weeks of continuous use.


Q: Is it normal to feel dizzy or tired when starting Adesan?

Regulatory documents indicate that dizziness is a commonly reported side effect. Fatigue (a feeling of tiredness or lack of energy) is also listed as a known adverse effect in some official product monographs. These effects may be more noticeable when first starting the medication.


Q: What happens if I accidentally skip a dose of Adesan?

If a dose is missed, regulatory guidance advises not to take a double dose to make up for the one that was skipped. The missed dose should be skipped, and the next scheduled dose should be taken at the usual time. Following this guidance helps maintain the correct exposure level of the medication.


Q: Is it safe to drink alcohol in moderation while on Adesan?

Official information warns that alcohol may have an additive effect in lowering blood pressure, which could potentially lead to hypotension (low blood pressure). This can increase feelings of dizziness or lightheadedness. The interaction with alcohol is a factor that is important to review with a healthcare provider.


Q: Is Adesan considered a 'strong' blood pressure medicine?

Adesan is classified as an Angiotensin II Receptor Blocker (ARB) used for the management of high blood pressure. Clinical studies demonstrate that the medication provides a significant and long-lasting reduction in arterial blood pressure across various doses and degrees of hypertension.


Q: How long do I have to take Adesan before seeing the full effect?

Official data confirms that the maximum blood pressure reduction is typically reached within four weeks of starting therapy at a given dose.


Q: What are some less common but serious side effects of Adesan to look out for?

Regulatory documents highlight rare but serious adverse effects, including angioedema (swelling of the face, lips, or throat), severe allergic reactions, and changes in blood cells like agranulocytosis. Any sign of severe swelling or a serious reaction requires immediate medical assessment.


Q: Can I take cold and flu medicines with Adesan?

It is important to know about interactions with specific ingredients in cold and flu medicines. Specifically, regulatory documents indicate that taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common in pain relievers and some cold medicines, may reduce Adesan's blood pressure-lowering effect. They may also increase the risk of kidney function problems, particularly in older individuals.


Q: Are there any specific dietary restrictions while taking Adesan?

Yes, caution is advised regarding potassium intake. Official information states that using potassium-containing salt substitutes or potassium supplements may increase the risk of hyperkalemia (high serum potassium levels) when taken with Adesan. This topic, including overall dietary plans, is important to discuss with a healthcare provider.


Q: How often do people typically need follow-up appointments when starting Adesan?

Close medical supervision and periodic monitoring are recommended when starting Adesan or after a dose change. This supervision typically involves monitoring key metrics such as blood pressure, kidney function, and electrolyte levels, especially during the initial two weeks and after any dose change.


Q: Can I take Adesan if I'm already taking ibuprofen for pain?

The combination of Adesan with NSAIDs such as ibuprofen may lead to two concerns noted in regulatory documents. Firstly, it may reduce the effectiveness of Adesan in lowering blood pressure. Secondly, it carries an increased risk of deterioration of kidney function.


Q: Do people develop a tolerance to Adesan over time?

Official clinical trial results indicate that the blood pressure-lowering effect of Adesan was maintained during long-term use. This suggests that effectiveness is generally sustained over time.


Q: Can Adesan cause a persistent cough like some other heart medicines?

Official information derived from clinical trials indicates that the incidence of cough was lower in patients taking Adesan (an ARB) compared to those taking ACE inhibitors, another class of heart medicines. Cough is typically not considered a common adverse effect associated with Adesan.


Q: How does Adesan affect the body's salt and water balance?

Adesan works by blocking the effects of a hormone called Angiotensin II. This hormone normally plays a key role in regulating the body's salt and water balance. By blocking this effect, Adesan helps relax blood vessels, which in turn contributes to lowering blood pressure.


Q: Can Adesan cause leg swelling or ankle swelling?

While swelling of the legs or ankles is not listed as a common side effect of Adesan itself, official safety information notes that swelling of the extremities (hands or feet) could potentially be a sign of kidney injury, which is a rare but possible serious effect of the medication.


Q: How is Adesan different from an ACE inhibitor?

Adesan is classified as an Angiotensin II Receptor Blocker (ARB). Its mechanism is to directly block the AT1 receptor. An ACE inhibitor, in contrast, works by blocking an enzyme. Because Adesan does not block the enzyme, it is generally associated with a lower risk of cough.


Q: How long does Adesan stay in your system?

Regulatory information on the drug's properties states that the elimination half-life of the active substance, candesartan, is approximately 9 hours. This is the time it takes for half of the medication to be cleared from the body.


Q: Is Adesan a diuretic (water pill)?

No, Adesan is not classified as a diuretic (or water pill). It belongs to the class of medications called Angiotensin II Receptor Blockers (ARBs). However, it may be prescribed in combination with a diuretic to achieve better blood pressure control.


Q: Does Adesan affect energy levels or cause fatigue?

Yes, fatigue (a feeling of being overly tired or low on energy) is listed as an adverse effect in the official regulatory documents for Adesan.


Q: Does Adesan have a risk of rebound hypertension if stopped suddenly?

Official clinical trial data indicates that when the medication was withdrawn, there was no evidence of rebound hypertension (a sharp increase in blood pressure). Clinical data indicates no rebound effect was observed after abrupt withdrawal of the medication.


Q: What are the main benefits of taking Adesan for high blood pressure?

For hypertension, the primary benefit documented in studies is a dose-dependent, sustained reduction in arterial blood pressure. In patients with heart failure, official research also shows it is indicated to reduce the risk of cardiovascular death and hospitalization due to heart failure.

How should Adesan be stored and disposed of?

Storage and Disposal Conditions

Adesan (candesartan cilexetil) tablets must be stored according to official regulatory requirements to ensure stability and effectiveness. The medication should be kept at Controlled Room Temperature (typically 20 to 25 Celsius), and must be stored below 30 Celsius (86 Fahrenheit).

Do not freeze the tablets. The medication must be kept in its original container, tightly closed, to protect it from excess moisture.

For safety, Adesan must be stored out of the sight and reach of children.

Disposal of any unused or expired tablets must be done in accordance with local requirements. The product must not be disposed of in sewers or wastewater to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Adesan found in:

A-Z Index: